肝癌“双弹头”组合单抗导向治疗的实验研究  

STUDY OF MONOCLONAL ANTIBODY CONJUGATED WITH DUAL-BULLETS FOR PILOT TREATMENTOF LIVER CANCER

作　　者：隋延仿[1] 刘利[1] 王文亮[1] 刘彦仿[1] 陈志南[1] 

机构地区：[1]第四军医大学病理学教研室

出　　处：《肿瘤》1995年第3期258-262,共5页Tumor

摘　　要：肝癌＂双弹头＂组合单抗导向治疗的实验研究隋延仿，刘利，王文亮，刘彦仿，陈志南第四军医大学病理学教研室（西安７１００３２）目前，肝癌免疫导向治疗在肝癌综合治疗中已发挥了重要作用，但是，已有资料显示，它的临床应用效果远不令人满意。我们在分析了这项治疗技术...Abstract The dual-bullets monoclonal antibody conjugates were consisted Of anti-liver cancer monoclonal antibodies (HAb18 and HAb25) conjugated with 131 I and adriamycin.The immune conjugate rate was 42.5%,the labeling rate was 49.8% and the comparative radioactivity was 6.88×104 Bq/μg (1.66μCi/μg).In the in vitro cytotoxicity study,the effect of dual-bullet MAb conjugate was markedly stronger than the mono-bullet MAb conjugate (P< 0.05). In the pilot treatment of tumor bearing mice, SPECT scanning spotted the tumor clearly at 168 hours with a tumor/liver ratio of 3.735±0.120, and had a much better therapeutic effect than other control groups (P<0. 05). These results demonstrated that:(1)the dual-bullets coordinate the merits of chemotherapy and radiotherapy, and thus enhance the tumor killing effect;(2)the MAb conjugates can pilot and concentrate the anti-cancer drug to the tumor target,and may some what eliminate the influesce of tumor heterogeneity on the pilot treatment.The authors believe that dual-bullets MAb conjugate pilot treatment may have opened a new prospect for comprehensive treatment of liver cancer.

关 键 词：肝肿瘤 免疫疗法 导向疗法 导向药物 实验 

分 类 号：R735.705[医药卫生—肿瘤]